The Obesity Association, a division of the American Diabetes Association (ADA), has issued new standards of care on the ...

Weight-loss experts reveal their major predictions for 2026, from advanced GLP-1 treatments to AI-driven personalized therapy ...

Recognizing obesity as a chronic condition can improve treatment by shifting the focus to biological factors. Get to know ...

Novo Nordisk's FDA-approved Wegovy pill marks a new era in obesity treatment, expanding access to GLP-1 therapy through ...

Novo Nordisk anticipates oral weight-loss drugs will capture one-third or more of the GLP-1 market by 2030, driven by ...

A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual ...

Obesity is a growing national health crisis, with nearly 40% of U.S. adults affected and about 10% having a severe form of ...

UK experts are warning that access to new weight-loss drugs could depend more on wealth than medical need. Strict NHS ...

The research team identified an enzyme called SCoR2 that removes nitric oxide from proteins that control fat buildup in the ...

A major study finds that weight loss drugs work while used, but weight and health benefits often return after stopping ...

Obstacles to preventing and treating obesity, including limited access to healthy foods, limited time to prepare meals and ...

Obesity is a complex chronic disease influenced by genetics, hormones, and environment, not a personal failure. Modern ...